ClinicalTrials.gg
Not yet recruitingNCT06557174Updated Aug 16, 2024

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

A Phase 1/2 interventional study of IMC-002 and mycophenolate mofetil, MMF in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.

Read the detailed description

This is a phase Ib/III study, including 2 stage, phase Ib study to find the dose for phase II study between 0.8mg/kg、1.2mg/kg dose level, Phase III study is a multi-center, randomized, double-blind, positive control study to evaluate the safety and efficacy of IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD)

02

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

Browse trials for

03

In context

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

This study's planned enrollment of 116 is above the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.

Browse Neuromyelitis Optica studies →

Lead sponsor

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years, inclusive, at the time of
  • Have a diagnosis of AQP4 antibody seropositive NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria
  • Confirmation of NMOSD diagnosis with AQP4+ antibodies
  • The EDSS score should be ≤7.0
  • Have clinical evidence of at least 1 documented attack or relapse (including first attack) in the last 2 years prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have received rituximab or other anti-CD20 drugs treatment within 6 months
  • Have been used any monoclonal antibodies or research drugs for immunomodulatory effects within 3 months or within 5 half-life periods of the drug.
  • Females who are pregnant or lactating.
  • Have active infection at screening, or recent serious infection (i.e., requiring intravenous antimicrobial therapy or hospitalization) ; history of or existing infection of (HIV), virus (HCV), or Mycobacterium tuberculosis. Patients must have negative test results for HCV antibody, HIV 1 and HIV 2 antibodies, and a mycobacterium tuberculosis test (test method to be determined).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    IMC-002

    intravenous injection of 0.8mg/kg、1.2mg/kg

    Drug: IMC-002

  • Active comparator
    mycophenolate mofetil, MMF

    mycophenolate mofetil will be administrated as monotherapy control for 0.2g daily oral.

    Drug: mycophenolate mofetil, MMF

Interventions

  • DrugAnti-CD47 Monoclonal Antibody IMC-002Studies of Anti-CD47 Monoclonal Antibody IMC-002Anti-CD47 Monoclonal Antibody IMC-002 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.

  • Drugmycophenolate mofetil, MMF

    daily oral 0.2g

06

What researchers measure

Primary outcomes

  1. Proportion of relapse-free patients

    Time frame: Up to Week 24

Secondary outcomes

  1. Time to first relapse (TFR)

    Time frame: Up to Week 24

  2. Mean change from baseline in Expanded Disability Status Scale (EDSS) score over the course of the study

    The Expanded Disability Status Scale ranges from 0 to 10 in 0.5 unit increments. Higher results represent higher levels of disability

    Time frame: Baseline (Day -28 to Day -1) to Week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Nov 2025, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2024
First posted
Aug 16, 2024
StartEst.
Oct 10, 2024
Primary completionEst.
Nov 10, 2025
CompletionEst.
Jul 10, 2026
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06557174
Lead sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Oct 10, 2024 (estimated)
Primary completion
Nov 10, 2025 (estimated)
Completion
Jul 10, 2026 (estimated)
Last update
Aug 16, 2024

Study contacts

jinhua zhou
Contact
jinhua.zhou@immuneonco.com
02138016387

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD47 Monoclonal Antibody IMC-002

Start the discussion